Jay Fram
  • Previous Rank
    263
  • Revenues ($M)
    11449
  • Revenue Percent Change
    6.4
  • Profits ($M)
    3702.8
  • Profits Percent Change
    4.4
  • Assets ($M)
    22877
  • Employees
    7400
  • Market Value — as of March 31, 2017 ($M)
    59046

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Company Info

CEOMichel Vounatsos
CEO TitleChief Executive Officer & Director
SectorHealth Care
IndustryPharmaceuticals
HQ LocationCambridge, MA
Websitewww.biogen.com
Years on Fortune 500 List8
Employees7,400

Key Financials (Last Fiscal Year)

Revenues ($M)$11,449
Profits ($M)$3,702.8
Assets ($M)$22,877
Total Stockholder Equity ($M)$12,140
Market Value — as of March 31, 2017 ($M)$59,046

Profit Ratios

Profit as % of Revenues32.3%
Profits as % of Assets16.2%
Profits as % of Stockholder Equity30.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)17
EPS % Change (from 2015)10.4%
EPS % Change (5 year annual rate)27.4%
EPS % Change (10 year annual rate)39%

Total Return

Total Return to Investors (2016)-7.4%
Total Return to Investors (5 year, annualized)20.8%
Total Return to Investors (10 year, annualized)19.1%